⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 1, 1998Expert Opinion on Investigational Drugs

Ongoing clinical trials of anti-platelet agents in the management of acute ischaemic coronary syndromes

View Full Paper

Ask AI

Bookmark

Share

Structured PICO

P

Population

Patients with acute ischaemic coronary syndromes

I

Intervention

Anti-platelet agents, specifically glycoprotein (GP) IIb/IIIa receptor antagonists

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This review highlights the promise of glycoprotein IIb/IIIa receptor antagonists in the management of acute ischemic coronary syndromes and notes ongoing trials to refine their use.

Cite This Study

Straznicky et al. (1998) studied this question.

synapsesocial.com/papers/6a6fea2a31a3df824328366d https://doi.org/10.1517/13543784.7.5.811

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsmeta-analysis · 1994 · 3,136 citations
2Randomized Trial of an Oral Platelet Glycoprotein IIb/IIIa Antagonist, Sibrafiban, in Patients After an Acute Coronary SyndromeRCT · 1998 · 180 citations
3The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromesreview · 1992 · 3,734 citations
4Effect of Ca <sup>2+</sup> on GP IIb-IIIa Interactions With Integrilinpreclinical · 1997 · 248 citations
5Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology.review · 1994 · 856 citations